The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule

被引:32
|
作者
Brucker, Mary C. [1 ]
King, Tekoa L. [2 ]
机构
[1] Georgetown Univ, Sch Nursing & Hlth Sci, Washington, DC USA
[2] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA
关键词
MEDICATIONS; HISTORY;
D O I
10.1111/jmwh.12611
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
As of 2015, the US Food and Drug Administration (FDA) discontinued the pregnancy risk categories (ABCDX) that had been used to denote the putative safety of drugs for use among pregnant women. The ABCDX system has been replaced by the FDA Pregnancy and Lactation Labeling Rule (PLLR) that requires narrative text to describe risk information, clinical considerations, and background data for the drug. The new rule includes 3 overarching categories: 1) pregnancy, which includes labor and birth; 2) lactation; and 3) females and males of reproductive potential. This article reviews the key components of the PLLR and clinical implications, and provides resources for clinicians who prescribe drugs for women of reproductive age. (C) 2017 by the American College of Nurse-Midwives.
引用
收藏
页码:308 / 316
页数:9
相关论文
共 50 条
  • [1] The Influence of the Food and Drug Administration Pregnancy and Lactation Labeling Rule on Drug Information Resources
    Harris, John Brock
    Holmes, Amy P.
    Eiland, Lea S.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (04) : 459 - 465
  • [2] Evaluation of Drug Labels Following the 2015 Pregnancy and Lactation Labeling Rule
    Byrne, John J.
    Saucedo, Alexander M.
    Spong, Catherine Y.
    JAMA NETWORK OPEN, 2020, 3 (08) : E2015094
  • [3] The new US Food and Drug Administration pregnancy and lactation labeling rules: Their impact on clinical practice
    Danesh, Melissa J.
    Murase, Jenny E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 310 - 311
  • [4] Knowledge of the new Food and Drug Administration pregnancy and lactation labeling rule (PLLR) among physicians and pharmacists
    Alem, Ghada
    Maneno, Mary K.
    Daftary, Monika
    Wingate, La'Marcus
    Ettienne, Earl
    Anyiwo, Adaobi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 384 - 384
  • [6] The US FDA pregnancy lactation and labeling rule - Implications for maternal immunization
    Gruber, Marion F.
    VACCINE, 2015, 33 (47) : 6499 - 6500
  • [7] The impact of the pregnancy and lactation labeling rule
    Byrne, John J.
    Saucedo, Alexander M.
    Spong, Catherine Y.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01) : S420 - S420
  • [8] US FOOD AND DRUG ADMINISTRATION (FDA) POSTMARKETING REQUIREMENTS AND COMMITMENTS RELATED TO DRUG DISPOSITION IN LACTATION AND PREGNANCY
    Ridge, S.
    Ramamoorthy, A.
    Guinn, D.
    Zineh, I.
    Fletcher, E. Pfuma
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S77 - S77
  • [9] Availability of Safe and Effective Therapeutic Options to Pregnant and Lactating Individuals Following the United States Food and Drug Administration Pregnancy and Lactation Labeling Rule
    Patel, Ashaka
    Sushko, Katelyn
    Mazer-Amirshahi, Maryann
    Fletcher, Elimika Pfuma
    Fusch, Gerhard
    Chan, Olsen
    Aghayi, Arya
    Chan, Anthony K. C.
    Lacaze-Masmonteil, Thierry
    Anker, Johannes Van Den
    Samiee-Zafarghandy, Samira
    JOURNAL OF PEDIATRICS, 2023, 259 : 1 - 11
  • [10] Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation
    Avachat, Charul
    Younis, Islam R.
    Birnbaum, Angela K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (06) : 1238 - 1242